June 18, 2026
The obesity therapeutics market continues to move at an extraordinary pace. What began as a race to develop effective GLP-1 therapies has evolved into a much broader competition involving dual- and triple-agonist molecules, oral formulations, next-generation incretins, combination therapies, and new indications extending well beyond weight management. Recent developments from companies such as Eli Lilly, Novo Nordisk, AstraZeneca, and others demonstrate that the obesity drug pipeline is expanding rapidly, with dozens of new candidates progressing through development and several oral therapies now entering the market.
As sponsors work to capitalize on this momentum, the demands placed on preclinical programs are becoming increasingly complex. Understanding pharmacology, safety, biodistribution, metabolic effects, cardiovascular outcomes, and long-term tolerability requires translational models capable of generating meaningful data before programs reach the clinic.
That is where Envol Biomedical provides a distinct advantage.
The Next Generation of Obesity Therapies Requires Better Preclinical Models
Today’s obesity drug developers are no longer focused solely on weight loss. Regulatory agencies, investors, and healthcare providers increasingly want evidence that new therapies can positively impact broader cardiometabolic health.
Recent clinical data continue to demonstrate this shift. GLP-1 and related therapies are being evaluated not only for obesity, but also for cardiovascular disease, chronic kidney disease, sleep apnea, liver disease, and other metabolic disorders. The World Health Organization’s recent obesity treatment guidelines further reinforce the growing recognition of obesity as a chronic disease requiring long-term management and comprehensive therapeutic strategies.
As a result, sponsors need preclinical models capable of generating meaningful data across multiple physiological systems. Non-human primates remain one of the most valuable translational models available because of their close physiological similarities to humans. Studies can provide critical insights into body weight changes, food consumption and satiety, glucose regulation, insulin sensitivity, cardiovascular biomarkers, clinical pathology endpoints, long-term safety profiles, and the pharmacokinetic and pharmacodynamic relationships that help define a therapy’s overall performance.
For developers pursuing increasingly sophisticated obesity programs, access to this type of translational data can significantly strengthen decision-making before entering costly clinical studies.
Why NHP Studies Continue to Play a Critical Role
As obesity therapies become more advanced, sponsors face growing pressure to accurately predict human responses.
Many next-generation programs are targeting multiple hormonal pathways simultaneously, while others are exploring oral delivery platforms, novel receptor combinations, or expanded indications that require a deeper understanding of systemic effects. Industry analysts estimate that well over 190 obesity-focused assets are now in development worldwide, highlighting both the opportunity and the competitive pressure facing sponsors today.
In this environment, generating high-quality translational data early in development can provide a meaningful competitive advantage. Well-designed NHP studies help sponsors establish optimal dose ranges, characterize efficacy signals, evaluate safety margins, and identify potential liabilities before they become expensive clinical challenges. These studies can also support regulatory discussions and provide additional confidence to investors evaluating the long-term potential of a program.
Envol Biomedical’s extensive experience with non-human primate research positions the organization to support these objectives throughout the development process.
Supporting the Full Spectrum of Obesity Drug Development
Envol’s capabilities extend far beyond routine animal studies.
Organizations developing obesity and metabolic disease therapies can access a comprehensive suite of preclinical services designed to support programs from early evaluation through IND-enabling development. These capabilities include pharmacokinetic and pharmacodynamic studies, toxicology support, clinical pathology and biomarker analysis, advanced imaging services, longitudinal sample collection, and specialized surgical procedures when unique delivery approaches are required. Each study benefits from experienced veterinary oversight and a scientific team focused on generating high-quality, actionable data.
The recent expansion of Envol’s GLP capabilities under the leadership of Director of Toxicology Dr. Daniela Schwotzer further strengthens the organization’s ability to support programs approaching regulatory submission. For sponsors seeking continuity throughout development, Envol offers the advantage of conducting studies within a highly integrated environment supported by experienced scientific, veterinary, and toxicology professionals working collaboratively toward common development goals.
Positioned for the Future of Metabolic Disease Research
The obesity market is entering a new phase. Oral GLP-1 therapies are gaining traction, next-generation candidates continue to demonstrate impressive efficacy, and developers are increasingly targeting broader cardiometabolic outcomes rather than weight loss alone. Recent industry forecasts suggest obesity therapeutics may become one of the largest pharmaceutical markets in history over the coming decade. (Reuters)
As competition accelerates, sponsors will need development partners capable of producing reliable, translational data that supports confident decision-making.
With extensive non-human primate expertise, expanding GLP capabilities, advanced imaging resources, and a growing reputation for supporting complex preclinical programs, Envol Biomedical is helping innovators move promising obesity therapies closer to patients. For organizations developing the next generation of obesity and metabolic disease treatments, choosing the right preclinical partner may be just as important as choosing the right molecule.